EMRISTA Landing Page

The Emerging Markets Thrombosis Investigator-Initiated Research Program (EMRISTA) has been established to fund innovative medical research from researchers across Pfizer’s Emerging Markets, including Africa, Asia, Latin America and the Middle East.

Investigators from the following countries are eligible to apply:

Africa
Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Congo, Cote D’ Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Kenya, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius Islands, Morocco, Mozambique, Nambia, Niger, Nigeria, Rwanda, Senegal, Sierra Leone, Somalia, South Africa, Sudan, Tanzania, Togo, Tunisia, Uganda, Western Sahara, Zaire (Democratic Republic of the Congo), Zambia, Zimbabwe

Asia
Bangladesh, Bhutan, Brunei, Cambodia, Hong Kong, India, Indonesia, Laos, Macau, Malaysia, Maldives, Myanmar, Nepal, Pakistan, Philippines, Singapore, Taiwan, Thailand, Vietnam

Latin America
Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay, Venezuela

Middle East
Saudi Arabia, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Oman, Qatar, Syria, United Arab Emirates, Yemen

The key objective is to encourage the generation of new data to improve patient care for those requiring oral anticoagulation treatment in relevant disease areas of unmet medical needs or special interest.

Highlights:

  • Submissions will be accepted until March 15, 2017.
  • Awards will be a maximum of $100,000 USD.
  • To ensure the highest level of scientific standards are maintained, proposals will be reviewed by an external Independent Review Committee (IRC that will be composed of experts from Latin America, the Middle East, Africa, Asia and the United States. Proposals are reviewed based on areas of interest, originality, scientific merit, and feasibility. The IRC will decide on prioritization for funding.

Potential conflicts of interest will be actively managed. IRC members may not submit a proposal, nor be co-author on any proposal submission to the program. IRC members will recuse themselves from review of any proposal where a conflict of interest exists.